Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...
DexCom Inc. (NASDAQ:DXCM) is one of the best medical technology stocks to invest in. On February 12, DexCom Inc. (NASDAQ:DXCM) shared its Q4 2025 earnings and reported $1.26 billion in quarterly ...
Dexcom reports 13% Q4 revenue growth to $1.26B, beating analyst expectations despite mixed analyst ratings and competitive pressures.
SHANGHAI, CHINA - JANUARY 25, 2022 - A 3M logo display of air-condensed thermal materials in a shopping mall in Shanghai, China, January 25, 2022. (Photo credit should read Wang Gang / Costfoto/Future ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
Investing.com - DexCom (NASDAQ: DXCM) reported fourth quarter EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $1.26B versus the consensus estimate of ...
DexCom is a leading healthcare stock that has seen significant growth, with shares returning close to 1,400% in the past decade. DXCM stock has faced resistance and is currently 37% below its all-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results